DREAM-HF-1 Study

UPMC has been selected as a center for the DREAM-HF-1 Study, a double-blind, randomized, sham-procedure-controlled, parallel-group efficacy and safety study of allogeneic mesenchymal precursor cells (rexlemestrocel-L) in patients with chronic heart failure due to left ventricular systolic dysfunction of either ischemic or nonischemic etiology.

We are currently enrolling men and women who have been diagnosed with heart failure with a reduced ejection fraction. The primary purpose of this study is to evaluate the effectiveness and safety of allogenic mesenchymal precursor cells (rexlemestrocel-L) versus a sham procedure to reduce recurrent non-fatal decompensated heart failure events.

The cells are human bone marrow derived from volunteer adult donors and are administered with intracardiac mapping during a single cardiac catheterization by our interventionalist.

Which patients are eligible?

Potential candidates for DREAM HF-1 must meet the following primary inclusion criteria:

  • Diagnosis of chronic heart failure with an EF of <40percent
  • NYHA Class III
  • 18 to 80 years old
  • Currently on stable and optimized GDMT
  • A previous HF hospitalization within nine months prior to screening procedures, or have had IV diuretic treatment for HF (without hospitalization) within nine months prior to screening procedures

Contact us

For a full list of inclusion/exclusion criteria or to refer a patient:

Marc Simon, MD, is the principal investigator at UPMC. If you know a patient who may qualify, please call Kristin Shoemaker, RN, BSN, CCRC, research nurse coordinator at 412-692-2769 or email HeartFailureClinicalTrials@upmc.edu.